PreveCeutical Files Cyclic Peptides And Uses Thereof in the EU and Australia
VANCOUVER, BC, July 24, 2023 /PRNewswire/ – PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress Cyclic peptides and uses thereof of its patent families.
Related news for (PRVCF)
- PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies
- PREVECEUTICAL INITIATES PREPARATION OF PROOF-OF-CONCEPT PRECLINICAL STUDY FOR ITS DIABETES & OBESITY DUAL GENE THERAPY PROGRAM
- PreveCeutical & Endosane Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD And Pharmacologically Relevant Doses Following Intranasal CBD Application
- PreveCeutical Showcases Dynamic Evolution in AI Strategy
- PreveCeutical Engages New to the Street for Production & Broadcasting Services